Candidiasis R&D Pipeline Analysis Report, Q4 2020
Candidiasis Pipeline Overview
The Q4 Candidiasis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Candidiasis, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Candidiasis Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Candidiasis disease overview, Candidiasis types, Candidiasis symptoms, causes, and FDA/EMA approved treatment options.
Candidiasis Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Candidiasis indication. The report presents near-term and long-term pipeline development trends and potential insights.
Candidiasis Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 39 companies. Business profiles and contact details of the companies actively perusing Candidiasis pipeline are assessed.
Candidiasis R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Candidiasis discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Candidiasis companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Candidiasis pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Candidiasis Pipeline Market News and Developments during 2020
The Candidiasis industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Candidiasis Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
The Q4 Candidiasis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Candidiasis, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
Candidiasis Disease Types, Symptoms, Causes, and Available Treatment Options
The comprehensive report on the indication presents Candidiasis disease overview, Candidiasis types, Candidiasis symptoms, causes, and FDA/EMA approved treatment options.
Candidiasis Pipeline Trends and Insights
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Candidiasis indication. The report presents near-term and long-term pipeline development trends and potential insights.
Candidiasis Company Trends and Insights
The report analyzes the development progress, current status, investments, partnerships, and other developments of 39 companies. Business profiles and contact details of the companies actively perusing Candidiasis pipeline are assessed.
Candidiasis R&D Pipeline Development Phase Trends and Insights
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Candidiasis discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Small Candidiasis companies look for licensing and collaboration partners
High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Candidiasis pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.
Candidiasis Pipeline Market News and Developments during 2020
The Candidiasis industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.
Candidiasis Mechanism of Action and Targets
Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.
New molecular entity details
Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.
Sources and Research Methodology
Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.
Scope and Coverage
- Candidiasis pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 39 companies are included including Acea Biotech Inc, Amplyx Pharmaceuticals Inc, Autoimmune Technologies LLC, Bakker Medical Srl, Beta Pharma Inc, Biomendics LLC, Biosergen AS, Cellix Bio Pvt Ltd, Cidara Therapeutics Inc, CSA Biotechnologies LLC, Destiny Pharma Plc, Fox Chase Chemical Diversity Center Inc, Fujifilm Toyama Chemical Co Ltd, General Biologicals Corp, Grupo Ferrer Internacional SA, Helix BioMedix Inc, Hennepin Life Sciences LLC, iCo Therapeutics Inc., Matinas BioPharma Holdings Inc, Mycovia Pharmaceuticals, Nanomerics Ltd, Next Science Ltd, Nosopharm SAS, Novabiotics Ltd, NovaDigm Therapeutics Inc, Novartis AG, Oryn Therapeutics, Pfizer Inc, Profem GmbH, Pulmocide Ltd, Riptide Bioscience Inc, Sano Chemicals Inc, Scynexis Inc, Sealife PHARMA GMBH, Shaanxi Synthetic Pharmaceutical Co Ltd, TGV Therapeutics, Toltec Pharmaceuticals LLC, Visterra Inc, Wellstat Vaccines LLC,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Candidiasis pipeline market
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. CANDIDIASIS PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Candidiasis Pipeline, 2020
2.2 Most focused Mechanism of Action in Candidiasis Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Candidiasis pipeline
2.5 Active Companies Developing Candidiasis pipeline
3. CANDIDIASIS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. CANDIDIASIS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Acea Biotech Inc
Amplyx Pharmaceuticals Inc
Autoimmune Technologies LLC
Bakker Medical Srl
Beta Pharma Inc
Biomendics LLC
Biosergen AS
Cellix Bio Pvt Ltd
Cidara Therapeutics Inc
CSA Biotechnologies LLC
Destiny Pharma Plc
Fox Chase Chemical Diversity Center Inc
Fujifilm Toyama Chemical Co Ltd
General Biologicals Corp
Grupo Ferrer Internacional SA
Helix BioMedix Inc
Hennepin Life Sciences LLC
iCo Therapeutics Inc.
Matinas BioPharma Holdings Inc
Mycovia Pharmaceuticals
Nanomerics Ltd
Next Science Ltd
Nosopharm SAS
Novabiotics Ltd
NovaDigm Therapeutics Inc
Novartis AG
Oryn Therapeutics
Pfizer Inc
Profem GmbH
Pulmocide Ltd
Riptide Bioscience Inc
Sano Chemicals Inc
Scynexis Inc
Sealife PHARMA GMBH
Shaanxi Synthetic Pharmaceutical Co Ltd
TGV Therapeutics
Toltec Pharmaceuticals LLC
Visterra Inc
Wellstat Vaccines LLC
5. CANDIDIASIS PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. CANDIDIASIS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2. CANDIDIASIS PIPELINE TRENDS AND INSIGHTS
2.1 Dominant Phase type of Candidiasis Pipeline, 2020
2.2 Most focused Mechanism of Action in Candidiasis Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Candidiasis pipeline
2.5 Active Companies Developing Candidiasis pipeline
3. CANDIDIASIS DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. CANDIDIASIS PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS
4.1 Acea Biotech Inc
Amplyx Pharmaceuticals Inc
Autoimmune Technologies LLC
Bakker Medical Srl
Beta Pharma Inc
Biomendics LLC
Biosergen AS
Cellix Bio Pvt Ltd
Cidara Therapeutics Inc
CSA Biotechnologies LLC
Destiny Pharma Plc
Fox Chase Chemical Diversity Center Inc
Fujifilm Toyama Chemical Co Ltd
General Biologicals Corp
Grupo Ferrer Internacional SA
Helix BioMedix Inc
Hennepin Life Sciences LLC
iCo Therapeutics Inc.
Matinas BioPharma Holdings Inc
Mycovia Pharmaceuticals
Nanomerics Ltd
Next Science Ltd
Nosopharm SAS
Novabiotics Ltd
NovaDigm Therapeutics Inc
Novartis AG
Oryn Therapeutics
Pfizer Inc
Profem GmbH
Pulmocide Ltd
Riptide Bioscience Inc
Sano Chemicals Inc
Scynexis Inc
Sealife PHARMA GMBH
Shaanxi Synthetic Pharmaceutical Co Ltd
TGV Therapeutics
Toltec Pharmaceuticals LLC
Visterra Inc
Wellstat Vaccines LLC
5. CANDIDIASIS PIPELINE DRUG PROFILES
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. CANDIDIASIS PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020
7. APPENDIX
7.1 About the Publisher
7.2 Sources and Research Methodology
